New hope for recurrent uterine cancer? drug combo enters early testing
NCT ID NCT06795009
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called zanzalintinib combined with standard chemotherapy (paclitaxel) in people with recurrent high-grade uterine or endometrial cancer. The main goal is to find the safest and most effective dose of the combination. About 36 participants will be enrolled, and researchers will also monitor side effects and how well the tumors respond to treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
NOT_YET_RECRUITINGSan Francisco, California, 94143, United States
-
University of New Mexico
NOT_YET_RECRUITINGAlbuquerque, New Mexico, 87106, United States
-
University of Oklahoma
NOT_YET_RECRUITINGOklahoma City, Oklahoma, 73104, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Can immunotherapy plus hormones spare the womb in early endometrial cancer?
- Can a new drug tackle Hard-to-Treat gynecologic cancers?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Can a Two-Drug combo tame a rare and aggressive gynecologic cancer?